Genovate Biotechnology

4130 · TPEx

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Phosphodiesterase 3 (PDE3)Small molecule
Atherosclerotic Cardiovascular Disease
Prusogliptin(Shanzeping)
Phase 3
DPP-4Small molecule
Type 2 Diabetes

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 May 2024Topline resultPMR (cilostazol ER)GBL23-001 (NCT06167265) bioequivalence study met its primary endpoints; NDA planned for the second half of 2025
US · Genovate Biotechnology Co., Ltd. · Source ↗

Financial reports

No financial reports recorded.